Several studies showed therapeutic potential of these GLP-1 agonists in animal models of neurodegenerative diseases such as Alzheimer’s disease [21], Parkinson’s disease [22], Huntington’s disease [23] and also after experimental traumatic brain injury [24]. The gene discussed is GLP1R; the disease is early-onset autosomal dominant Alzheimer disease.